16 Oct Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication
NG101 Significantly Reduced Incidence of Nausea by 40% and Frequency of Vomiting by 56% without Changing the Safety Profile of the GLP-1 Agonist WOBURN, MA, October 16, 2024 – Neurogastrx, Inc. today announced positive topline results from a new study of NG101 (metopimazine mesylate) showing...